This interview with a Spain-based key opinion leader (KOL) offers insights into current treatment practices, prescribing behaviors, and late-phase pipeline therapies in Small Cell Lung Cancer (SCLC). The discussion covers disease staging, diagnostic approaches, first- and second-line treatment selection, and the evolving role of immunotherapy and antibody-drug conjugates (ADCs) in the SCLC treatment landscape. Additional topics include patient eligibility for emerging therapies, treatment sequencing in the relapsed/refractory setting, unmet needs, and the potential impact of novel pipeline agents.

The standard of care for extensive-stage SCLC in Spain relies on carboplatin/etoposide plus atezolizumab as first-line therapy, as durvalumab remains unapproved in the country. The expert noted that both tarlatamab and lurbinectedin are not yet approved in Spain, with topotecan remaining the standard second-line option. The KOL expressed a strong preference for tarlatamab over lurbinectedin based on DeLLphi trial data, and anticipated lurbinectedin's potential future role as a maintenance or first-line agent. Pipeline ADCs were discussed with cautious optimism tempered by toxicity concerns, while DLL3-targeted BiTE therapies were viewed as more promising. Key unmet needs include developing more durable, less toxic therapies and advancing the most effective agents to the first-line setting.

This interview was conducted on April 20, 2026. 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.